Essentially uniform concordance between model and expert assessment. Possibility to use as a point-of-care/decision-support tool? Ability to distinguish specific cytogenetic/molecular subtypes & prognosis by morphology-based AI unclear but of interest. (2/2) #ASH24

The ASH annual meeting is the premier venue for #hematology collaborations across borders 🌏

#ASHThrowback to a meeting with ASH and the Mediterranean Partner Societies at #ASH24. Belinda Avalos, MD #ASH25

International community, share your throwbacks from past ASH meetings! #HemeSky

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches Mantle cell lymphoma (MCL) represents a relatively uncommon, heterogeneous lymphoma associated with limited overall survival. Targeting of the B-cell receptor pathway in relapsed disease with covalent...

Fastest review I have ever been involved with - written almost entirely on the plane back from #ASH24
#lymSM
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

Thanks to all the participants, speakers, and sponsors who made HOA LA possible!

Gracias a todos los participantes, ponentes y patrocinadores que hicieron posible este encuentro único en HOA LA.

#ASH24 #HighlightsOfASH #ASHLA #Hematología #Medicina #HemeSky #MedSKy

SOHO Insider Emavusertib Shows Promise in High-Risk MDS Emavusertib yields remissions in high-risk MDS with spliceosome mutations, per ASH 2023 TakeAim trial data."

Preliminary TakeAim data shows promise of #emavusertib in higher-risk #MDS #ASH24 #ASHthrowback

sohoinsider.com/meetings-con...

📅 Last call! Join ASH and Société Marocaine d'Hématologie for a practice-changing weekend!

Learn the clinical applications of groundbreaking #ASH24 research in a small-meeting, interactive environment where you can get all your questions answered:
bit.ly/4gQ2zQD

#HemeSKy #Hematology

New paper in @bloodjournal.bsky.social by Wuliji et al on their work on social determinants & allo-HCT in AML! This was also a plenary at #ASH24

-SDOH are associated w/ access to transplant
-for those that get transplant those SDOH don't seem to impact survival

ashpublications.org/blood/articl...

🎥 Dr Ian Bouligny shares the results of a Phase II trial investigating ipilimumab, nivolumab, or ipilimumab + nivolumab with/without azacitidine in R/R MDS:

👉 buff.ly/m8zEtUu 👈

#ImmunoOnc #ASH24 #MDSsm #HemOnc #CTSM #TrialUpdate #BloodSky #Hemesky

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL @ASH_hematology #ASH24 #lymsm www.onclive.com/view/fixed-d...

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis The POIESIS trial is evaluating navtemadlin plus ruxolitinib in JAK inhibitor–naive patients with myelofibrosis with a suboptimal response to ruxolitinib.

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis @ash.hematology.org #ASH24 #hematology
www.onclive.com/view/navtema...

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS
@mdanderson.bsky.social @ash.hematology.org #ASH24 #lymsm #hematology
www.onclive.com/view/ivoside...

📢 Highlights of ASH® in Latin America | 25-26 abril | Punta del Este

🔬 Actualizaciones de la ASH Annual Meeting #ASH24
🩸 Sunset Session
📖 Meet & Greet con el Dr. Jorge Cortes
🍽 Lunch with the Experts

¡Inscríbete! 🔗 hematology.org/meetings/highlights/latin-america

#Hematología #Oncología

📢 Highlights of ASH® in Latin America | 25-26 abril | Punta del Este

🔬 Atualizações da ASH Annual Meeting #ASH24
🩸 Sunset Session
📖 Meet & Greet com Dr. Jorge Cortes
🍽 Lunch with the Experts

Garanta sua participação! 🔗 hematology.org/meetings/highlights/latin-america

#Hematologia #Oncologia

Combination Regimens Expand CLL Treatment Paradigm During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Combination Regimens Expand CLL Treatment Paradigm @drmdavids.bsky.social @harvardmed.bsky.social @danafarber.bsky.social @kumedcenter.bsky.social @columbiacancer.bsky.social @ash.hematology.org #ASH24 #leusm #hematology
www.onclive.com/view/combina...

Paper: Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study [12/724] Cheruvalath et al. @MeeraMohanMD #ASH24 Abst 256 ash.confex.com/ash/2024/web... #mmsm #IDonc #SuppOnc HT @RahulBanerjeeMD

Paper: A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma [Dec 7, 2024] @EagleMyeloma et al. #ASH24 Abst 255
ash.confex.com/ash/2024/web... #mmsm #IDonc

5 razones para participar en el 2025 Highlights of ASH® in Latin America:
1️⃣ Actualizaciones de la ASH Annual Meeting
2️⃣ Lunch with the Experts
3️⃣ Networking con especialistas
4️⃣ Meet & Greet con el @jcortesmd.bsky.social
5️⃣ Sunset Session
Inscríbete👉 hematology.org/meeti...
#ASH24

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma @ash.hematology.org #ASH24 #mmsm #hematology
www.onclive.com/view/etentam...

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Ibrutinib/Venetoclax/Obinutuzumab Controls Disease at 5 Years in Newly Diagnosed MCL @chunantes.bsky.social @ash.hematology.org #ASH24 #lymsm #hematology
www.onclive.com/view/ibrutin...

Had a chance to listen to our latest podcast?🎙️

👉Listen here: https://buff.ly/4bczFbp

Join Vaishali Sanchorawala and Ashutosh Wechalekar as they discuss the latest #amyloidosis updates, including:

⭐The #ANDROMEDA trial
⭐Risk stratification
⭐#MRD
⭐CAR-T

#HemOnc #ImmunoOnc #ASH24

Stay ahead in hematology! 🚀 Watch our latest video with @jcortesmd.bsky.social to discover how Highlights of ASH brings groundbreaking research and clinical updates to you—wherever you are. 🩸🔬

🌍 Upcoming Global Events:
🇲🇦 Casablanca: Apr 4-5
🇺🇾 Punta del Este: Apr 25-26

#ASH24 #Hematology #HemeSky

Want the latest updates on #amyloidosis?🩸

🎧Listen to our podcast: https://buff.ly/3QrP9yn

Featuring Vaishali Sanchorawala & Ashutosh Wechalekar, who discuss:

👉The ANDROMEDA trial
👉Risk stratification
👉MRD
👉CAR-T therapies

#HemOnc #ASH24 #ImmunoOnc

Just weeks remain until #hematology professionals across the Mediterranean, Middle East, and North Africa region reunite over the most influential research from #ASH24 and discuss best practices for clinical application.

Plan to attend: bit.ly/4gQ2zQD

#BloodSky #HemeSKy

#ASH24 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in #CLL.

www.targetedonc.com/view/highlig...

If you're interested in #SickleCellDisease, #Thalassemia, or #Hemophilia, don't miss out on our recent podcast episode!🎧🩸

Listen to key updates from leading experts on your favorite podcast platform:

👉 https://buff.ly/3EAYrWh 👈

#CTSM #ASH24 #TrialUpdate #Hematology

Almoce com especialistas e aprofunde-se nos principais temas da hematologia no 2025 Highlights of ASH® in Latin America.
✅ Escolha sua mesa e tema no 1º dia
✅ Participe de discussões interativas no 2º dia
🔗 Inscreva-se agora! 👉 hematology.org/meeti...

#ASH24 #Hematologia

Almuerza con especialistas y profundiza en los principales temas de la hematología en el 2025 Highlights of ASH® in Latin America.

✅ Elige tu mesa y tema el 1º día
✅ Participa en discusiones interactivas el 2º día
🔗 ¡Inscríbete ahora! 👉 hematology.org/meeti...

#ASH24 #Hematología

The latest breakthroughs in #AML from #ASH24 are here! Oncology experts review the most impactful research, emerging therapies, and what these findings mean for clinical practice.
📹 Watch the full analysis: ow.ly/uFuS50V2ZrE

#OncEd #MedOnc

The recent ASH annual meeting offered more than just scientific discoveries: https://bit.ly/4gIY0qh

#ASH24 #ASHThrowback #HemeSky #BloodSky @juliperezbot.bsky.social
3/4